[1]
Jayaraman, R.; Pasha, M.K.; Williams, A.; Goh, K.C.; Ethirajulu, K. 2015. Metabolism and Disposition of Pacritinib (SB1518), an Orally Active Janus Kinase 2 Inhibitor in Preclinical Species and Humans. Drug Metab. Lett., Jan 18 [Epub ahead of print].
[2]
Jayaraman, R; Pilla Reddy, V; Pasha, MK; Wang, H; Sangthongpitag, K; Yeo, P; Hu, CY; Wu, X; Xin, L; Goh, E; New, LS; Ethirajulu, K 2011. Preclinical
metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics. Drug
Metab Dispos, Dec 39(12), 2219-32.
[3]
Ethirajulu Kantharaj and Ramesh Jayaraman. 2011. Histone deacetylase inhibitors as therapeutic agents for cancer therapy: Drug Metabolism and pharmacokinetic
properties Chapter 5 "Drug Development - A Case Study Based Insight into Modern Strategies", book edited by Chris Rundfeldt, ISBN
978-953-307-257-9, Published: December 7, 2011 under CC BY 3.0 license., 2011.
[4]
Younes, A.; Romaguera, J.; Fanale, M.; McLaughlin, P.; Hagemeister, F.; Copeland, A.; Neelapu, S.; Kwak, L.; Shah, J.; de Castro Faria, S.; Hart, S.; Wood, J.; Jayaraman, R.; Ethirajulu, K.; Zhu, J. 2012. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J. Clin. Oncol., 30(33), 4161-4167.
[5]
Madan, B.; Goh, K.C.; Hart, S.; William, A.D.; Jayaraman, R.; Ethirajulu, K.; Dymock, B.W.; Wood, J.M. 2012. SB1578, a novel inhibitor of JAK2, FLT3, and c-Fms for the treatment of rheumatoid arthritis. J. Immunol., 189(8), 4123-4134.
[6]
Pasha, M.K.; Jayaraman, R.; Reddy, V.P.; Yeo, P.; Goh, E.; Williams, A.; Goh, K.C.; Kantharaj, E. 2012. Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab. Lett., 6(1), 33-42.
[7]
William AD, Lee AC, Goh KC, Blanchard S, Poulsen A, Teo EL, Nagaraj H, Lee CP, Wang H, Williams M, Sun ET, Hu C, Jayaraman R, Pasha MK, Ethirajulu K, Wood JM, Dymock BW. 2012. Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa1(25), 2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer. J. Med. Chem., 55(1), 169-196.
[8]
KC Goh, V Novotny-Diermayr, S Hart, LC Ong, YK Loh, A Cheong, YC Tan, C Hu, R Jayaraman, AD William, ET Sun, BW Dymock, KH Ong, K Ethirajulu, F Burrows and JM Wood. 2011. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties. Leukemia, 26(2), 236-243.
[9]
William AD, Lee AC, Blanchard S, Poulsen A, Teo EL, Nagaraj H, Tan E, Chen D, Williams M, Sun ET, Goh KC, Ong WC, Goh SK, Hart S, Jayaraman R, Pasha MK, Ethirajulu K, Wood JM, Dymock BW. 2011. Discovery of the Macrocycle SB1518, a Potent JAK2/FLT3 Inhibitor for the Treatment of Myelofibrosis and Lymphoma. J. Med. Chem., 2011, Jul 14; 54(13), 4638-4658.
[10]
Hart S, Goh KC, Novotny-Diermayr V, Hu CY, Hentze H, Tan YC, Madan B, Amalini C, Loh YK, Ong LC, William AD, Lee A, Poulsen A, Jayaraman R, Ong KH, Ethirajulu K, Dymock BW, Wood JW. 2011. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia, 25(11), 1751-1759.
[11]
Jayaram R, Shandil RK, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Kantharaj E, Balasubramanian V. 2004 Isoniazid Pharmacokinetics-Pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob. Agents and Chemother., 48(8), 2951-2957.
